Prolonged-release mesalazine: A review of its therapeutic potential in ulcerative colitis and Crohn's disease

Drugs

Volumn 59, Issue 4, 2000, Pages 929-956

  Clemett, Delyth ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROPEROXYARACHIDONIC ACID; 5 HYDROPEROXY 6,8,11,14 ICOSATETRAENOIC ACID; ACETYL MESLAZINE; ALPHA INTERFERON; BALSALAZIDE; BUDESONIDE; DRUG METABOLITE; EUDRAGIT; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LEUKOTRIENE B4; LEUKOTRIENE C4; LIPOXYGENASE; MESALAZINE; OLSALAZINE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SALAFOLK; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; COLON CROHN DISEASE; COLON DISEASE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; ILEORECTAL ANASTOMOSIS; LIMB DISEASE; NAUSEA; NEPHROTOXICITY; REVIEW; ULCERATIVE COLITIS; VOMITING;

EID: 0034057079     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059040-00016     Document Type: Review

References (128)

1. 1. Martin F. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease: an update. Dig Dis Sci 1987; 32 (12Suppl.): 57S-63S
2. 2. Azad Khan AK, Piris J, Truelove SC. An experiment of determine the active therapeutic moiety of sulphasalazine. Lancet 1979; II (8044): 892-5
3. 3. Sehröder H, Price E, Evans DA. Acetylator phenotype and adverse events of sulphasalazine in healthy subjects. Gut 1972; 13 (4): 278-84
4. 4. Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16 (6): 738-40
5. 5. Geier DL, Miner Jr PB. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992; 93: 199-208
6. 6. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993; 33: 712-8
7. 7. Järnerot G. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155-8
8. 8. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8
9. 9. Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990; 78: 119-25
10. 10. Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-83
11. 11. Travis SPL, Jewell DP. Salicylates for ulcerative colitis - their mode of action. Pharmacol Ther 1994; 63: 135-61
12. 4 in isolated colonic mucosal cells. Curr Med Res Opin 1996; 13 (7): 417-25
13. 13. Capasso F, Tavares IA, Bennett A. Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid. Drugs Exp Clin Res 1991; 17: 351-3
14. 14. Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 929-32
15. 15. Di Paolo MC, Merrett MN, Crotty B, et al. 5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Gut 1996; 38: 115-9
16. 16. Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991; 36: 174-8
17. 17. Sandoval M, Liu X, Mannick EE, et al. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997; 113: 1480-8
18. 18. Horn H, Preclik G, Stange EF, et al. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991; 26: 867-79
19. 19. Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. Eur J Gastroenterol Hepatol 1992; 4: 837-41
20. 20. Eliakim R, Karmeli F, Chorev M, et al. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 1992; 27: 968-72
21. 21. Fox C, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36: 179-84
22. 22. Rachmilewhz D, Karmeli F, Eliakim R. Platelet-activating factor - a possible mediator in the pathogenesis of ulcerative colitis. Scand J Gastroenterol 1990; 25 Suppl. 172: 19-21
23. 23. Bruin KF, Hommes DW, Jansen J, et al. Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995; 7: 791-5
24. 24. Mahida YR, Lamming CED, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1β production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991; 32: 50-4
25. 25. Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995; 272: 399-406
26. 26. Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. Eur J Gastroenterol Hepatol 1993; 5: 515-20
27. 27. Dallegri F, Ottonello L, Ballestrero A, et al. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 184-6
28. 4. Dig Dis Sci 1987; 32 (12): 1380-8
29. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86 (3): 453-60
30. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91 (4): 837-44
31. 31. Guimbaud R, Izzo A, Martinolle JP, et al. Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Dig Dis Sci 1995; 40 (2): 2635-40
32. 32. Eliakim R, Karmeli F, Razin E, et al. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine and prednisolone. Gastroenterology 1988; 95 (5): 1167-72
33. 33. Thyssen E, Turk J, Bohrer A, et al. Quantification of distinct molecular species of platelet-activating factor in ulcerative colitis. Lipids 1996; 31 Suppl.: S 255-9
34. 34. Sobhani I, Hochlaf S, Denziot Y, et al. Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut 1992; 33 (9): 1220-5
35. 35. Crotty B, Hoang P, Dalton HR, et al. Salicylates used in inflammatory bowel disease and colchicine impair interferon-γ induced HLA-DR expression. Gut 1992; 33: 59-64
36. 36. Crotty B, Rosenberg WMC, Aronson JK, et al. Inhibition of binding of interferon-γ to its receptor by salicylates used in inflammatory bowel disease. Gut 1992; 33: 1353-7
37. 37. Horie Y, Chiba M, Suzuki T, et al. Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2. J Gastroenterol 1998; 33 (1): 39-47
38. 38. Selby WS, Janossy G, Mason DY, et. al. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983; 53 (3): 614-8
39. 39. McDonald GB, Jewell DP. Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J Clin Pathol 1987; 40: 312-7
40. 40. Ishii N, Chiba M, Iiziuka M, et al. Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-α and interferon-γ. Scand J Gastroenterol 1994; 29 (10): 903-7
41. 41. Oberhuber G, Püspök A, Peck-Radosavlevic M, et al. Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease. Am J Surg Pathol 1999; 23 (8): 970-6
42. 42. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κ-B activation in mouse colonocytes. Gastroenterology 1999; 116: 602-9
43. 43. Greenfield SM, Hamblin AS, Shakoor ZS, et al. Inhibition of leucocyte adhesion molecule upregulation by tumour necrosis faclor α: a novel mechanism of action of sulphasalazine. Gut 1993; 34: 252-6
44. 44. Simmonds AJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992; 103 (1): 186-96
45. 45. Keshavarzian A, Sedghi S, Kanofsky J, et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1002; 103(1): 177-85
46. 46. Prónai L, Yukinobu I. Lang I, et al. The oxygen-centered radicals scavenging activity of sulphasalazine and its metabolites. A direct protection of the bowel. Acta Physiol Hung 1992; 80: 317-23
47. 47. Greenfield SM, Punchard NA, Thompson RPH. Inhibition of red cell membrane lipid peroxidalion by sulphasalazine and 5-aminosalicylic acid. Gut 1991; 32: 1156-9
48. 48. Simmonds NJ, Millar AD, Blake DR, et al. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999; 13: 363-72
49. 49. Yu DK, Morrill B, Eichmeier LS, et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. Eur J Clin Pharmacol 1995; 48: 273-7
50. 50. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 2000; 14: 163-9
51. 51. Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy 1994; 14: 385-98
52. 52. Rasmussen SN, Bondesen S, Hvidherg EF, et al. 5-Aminosalicylic acid in a slow-release prepararation: bioavailability, plasma level, and excretion in humans. Gastroenterology 1982; 83: 1062-70
53. 53. Stolk LM, Rietbroek R, Wiltink EH, et al. Dissolution profiles of mesalazine formulations in vitro. Pharm Weekbl Sci 1990; 12: 200-4
54. 54. Larouche J, Morais J, Picard M, et al. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment Pharmacol Ther 1995; 9: 315-20
55. 55. Wilding IR. A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Pract Gastroenterol 1999: 1-8
56. 56. Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427-33
57. 57. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-amino-salicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523-33
58. 58. Christensen LA, Fallingborg J, Jacobsen BA, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994; 8: 289-94
59. 59. Christensen LA, Slot O, Sanchez G, et al. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol 1987; 23: 365-9
60. 60. Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol 1992; 27: 863-8
61. 61. Bondesen S, Tage-Jensen U, Jacobsen O, et al. 5-Aminosalicylic acid in patients with an ileo-rectat anastomosis. A comparison of the fate of sulfasalazine and Pentasa. Eur J Clin Pharmacol 1986; 31: 23-6
62. 62. Bondesen S, Hegnhoj J, Larsen F, et al. Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and Per Os slow-release formulation. Dig Dis Sci 1991; 36: 1735-40
63. 63. Daneshmend TK, Hendrickse M, Salzmann M, et al. Does systemic absorption of 5-aminosalicylic acid from olsalazine (Dipentum®) and mesalazine (Asacol® and Pentasa®) differ significantly in ulcerative colitis? [abstract]. Gut 1994; 35 Suppl. 4: 233
64. 64. Staerk-Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, scram values, and unnary excretion. Gut 1990; 31: 1271-6
65. 65. Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand 1994; 74: 399-402
66. 66. Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). Clin Pharmacokinet 1990; 19: 94-125
67. 67. Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician 1998; 57: 57-68
68. 68. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204-11
69. 69. Ardizzone S, Molteni P, Bollani S, et al. Guidelines for the treatment of ulcerative colitis in remission. Bur J Gastroenterol Hepatol 1997; 9: 836-41
70. 70. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for the treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188-97
71. 71. Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30 Suppl. 8: 108-11
72. 72. Farup PG, Oddsson E, Hinterleitner T. Mesalamine 4 g prolonged release granules b.i.d. and q.i.d. versus tablets q.i.d. for mild/moderate ulcerative colitis [abstract]. Gastroenterology 1999; 116 (2): A713
73. 73. Fockens P, Mulder CJJ, Tytgat GNJ, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 1025-30
74. 74. Mulder CJ, Tytgat GNJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis [see comments]. Gastroenterology 1988; 95: 1449-53
75. 75. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995; 40: 296-304
76. 76. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92 (4): 559-66
77. 77. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease [letter]. Gastroenterology 1994; 107: 632-3
78. 78. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group [see comments]. Gastroenterology 1993; 104: 1293-301
79. 79. Hanauer SB, Krawitt EL, Robinson M, et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa®). Am J Gastroenterol 1993; 88: 1343-51
80. 80. Colombel J-F, Lémann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-8
81. 81. Thomsen OØ, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998; 339: 370-4
82. 82. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987; 22: 877-83
83. 83. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990; 45: 88-92
84. 84. Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohns disease : a multicenter placebo-controlled sludy [in French]. Ann Gastroenterol Hepatol 1993; 29: 251-6
85. 85. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37: 29-32
86. 86. Sutherland LR, Martin F, Bailey RJ, et al. 5-Aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn's disease [abstract]. Gastroenterology 1995; 108 Suppl.: 924
87. 87. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995; 108: 345-9
88. 88. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118: 264-73
89. 89. Bondesen S, Danish 5-ASA-group. Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial [abstract]. Scand J Gastroenterol 1991; 26 Suppl. 183: 68
90. 90. Modigliani R, Colombel J-F, Dupas J-L, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996; 110: 688-93
91. 91. Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17: 186-92
92. 92. Robinson M, Hanauer S, Hoop R, et al. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 27-34
93. 93. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995; 40: 931-5
94. 94. Zbrozek A, Hoop R, Robinson M, et al. Test of an instrument to measure function-related quality of life in patients with ulcerative colitis. Pharmacoeconomics 1993; 4 (1): 31-9
95. 95. Kotanagi H, Ito M, Koyama K, et al. Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease. J Gastroenterol 1998; 33: 571-4
96. 96. Netzer P. Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease [in German]. Schweiz Med Wochenschr 1995; 125: 2438-42
97. 97. Declerek D, Wallaert B, Demarcq-Delerue G, et al. Diffuse interstitial pneumonia linked to 5-aminosalicylate [in French]. Rev Mal Respir 1994; 11: 292-3
98. 98. Janowski M, Laglenne S, Beaufils F. Hypersensitivity pneumopathy during treatment with mesalazine (Pentasa®). The value of bronchoalveolar lavage [in French]. Rev Med Interne 1992; 13: 545
99. 99. Besseau M, Delchier JC, Blazquez M, et al. Acute pancreatitis induced by mesalazine (Pentasa) [in French]. Gastroenterol Clin Biol 1991; 15 (2): 174-5
100. 100. Gron I, Winther A. Exanthema in two patients with ulcerative colitis treated with Pentasa [in Danish]. Ugeskr Laeger 1988; 150:32
101. 101. Kapur KC, Williams GT, Allison MC. Mesalazine induced exacerbation of ulcerative colitis. Gut 1995; 37: 838-9
102. 102. Marteau P, Nelet F, Lu LM, et al. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949-56
103. 103. Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12: 1101-8
104. 104. Tennenbaum R, Marteau P, Elefant E, et al. Pregnancy outcome in inflammatory bowel disease [in French]. Gastroenterol Clin Biol 1998; 23 (5): 464-9
105. 105. Pardi DS, Tremaine WJ, Sandborn WJ, et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504-14
106. 106. Corrigan G, Stevens PE. Interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14 (1): 1-6
107. 107. World MJ, Stevens PE, Ashton MA, et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614-21
108. 108. Howard G, Lynn KL. Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring. Aust N Z J Med 1998; 28: 346
109. 109. Brouillard M, Gheerbrant JD, Gheysens Y, et al. Interstitial nephritis and mesalazine: three new cases [in French]. Gastroenterol Clin Biol 1998; 22: 724-6
110. 110. Be Broe ME, Stolear JC, Nouwen EJ, et al. 5-aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link? Nephrol Dial Transplant 1997; 12: 1839-41
111. 111. Colombel J-F, Brabant G, Gubler M-C, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? [letter]. Lancet 1994; 344: 620-1
112. 112. Mulder CJ, Tytgat GN, Dekker W, et al. Pentasa in lieu of sulfasalazine [letter]. Ann Intern Med 1988; 108: 911-2
113. 113. Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22 (6): 452-5
114. 114. Steeno OP. Side-effects of salazopyrin on male fertility. Eur J Obstet Gynecol Reprod Biol 1984; 18 (5-6): 361-4
115. 115. Kjaergaard N, Christensen LA, Lauritsen JG, et al. Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis. Scand J Gastroenterol 1989; 24 (7): 891-6
116. 116 Zelissen PM, van-Hattum J, Poen H, et al. Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scand J Gastroenterol 1988; 23: 1100-4
117. 117. Roberts Pharmaceuticals. Pentasa prescribing information. Eatontown, New Jersey, USA, 1998
118. 118. Pentasa data sheet. Ferring Pharmaceutical. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: DataPharm Publications Ltd, 1999: 437-8
119. 119. Russel MGVM, Stockbrügger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417-27
120. 120. Harting JW. New developments in the pharmacotherapy of inflammatory bowel disease. Pharm Weekbl Sci 1992; 14: 275-86
121. 121. Glickman RM. Inflammatory bowel disease: ulcerative colitis and Crohn's disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 14th ed. v. 2. New York: McGraw-Hill, 1998: 1633-45
122. 122. Ardizzone S, Bianchi PG. A practical guide to the management of distal ulcerative colitis. Drugs 1998; 55: 519-42
123. 123. Brynskov J, Rasmussen SN. Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 1996; 216: 175-80
124. 124. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 1984; 101 (3): 377-86
125. 125. Singleton JW, Law DH, Kelley Jr ML, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 44 (4 Pt 2): 870-82
126. 126. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465-73
127. 127. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99 (4): 956-63
128. 128. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33 (3): 1150-1